What happens when you take metformin with alpha-lipoic acid?
Alpha-lipoic acid (ALA) is a fatty acid that the body produces in tiny amounts inside the mitochondria. As a supplement, it is taken at much higher doses (usually 300-600 mg per day) for diabetic peripheral neuropathy, where European studies have shown it can reduce burning, numbness, and pain in the feet. It is also marketed as a "glucose support" antioxidant. Metformin is a biguanide that reduces hepatic glucose output and improves muscle insulin sensitivity.
The interaction is pharmacodynamic, not pharmacokinetic - meaning ALA does not change how much metformin you absorb or how fast you clear it. Instead, both compounds independently nudge blood glucose down. ALA improves glucose uptake into skeletal muscle and has some insulin-sensitizing activity, particularly in patients with type 2 diabetes or metabolic syndrome. Stack it on top of metformin and the glucose-lowering effects can add up.
The good news is that the additive effect is usually mild. Drugs.com classifies the interaction as minor, and in healthy volunteers, single doses of ALA combined with sulfonylureas did not produce a measurable interaction. Larger trials in diabetics have shown that ALA's blood-glucose-lowering effect is real but modest - not enough to require a metformin dose change in most patients. The risk shows up more clearly in vulnerable patients: the very thin, the malnourished, people on beta-blockers (which mask early warning signs), and anyone whose A1c is already at or near goal.
Why is this important?
ALA is one of the most widely used supplements among people with diabetes because diabetic neuropathy is so common and so under-treated. If you are taking metformin, there is a meaningful chance you have nerve symptoms in your feet, and there is a meaningful chance you have read about ALA online or had it recommended by a podiatrist or naturopath.
The interaction is mild enough that you should not be afraid of the combination - but it is real enough that you should not be casual about it either. Many patients add ALA without telling their primary doctor because they think of it as a "vitamin." If your fasting glucose drops by 10-15 mg/dL after starting ALA, your prescriber should know, because that information can change A1c interpretation and dose decisions.
There is a separate biotin concern worth flagging here. ALA shares a transporter with biotin in the gut, and chronic high-dose ALA can deplete biotin levels. Patients on long-term ALA sometimes need supplemental biotin. This does not change the metformin interaction directly, but it is worth knowing if you plan to take ALA daily for months.
What should you do?
Discuss ALA with the clinician managing your diabetes before starting. A typical neuropathy dose is 600 mg per day, often split into two 300 mg doses. Take ALA on an empty stomach (30 minutes before food) for best absorption, which is different from metformin, which is best taken with food. This means in practice you can take ALA in the morning before breakfast and metformin with breakfast - no spacing conflict.
Check your blood sugar more often during the first month, especially fasting and pre-dinner readings. If you use a continuous glucose monitor, watch for an upward shift in time-in-range below 80 mg/dL. If you get a reading under 70 mg/dL or notice symptoms - sweating, shakiness, hunger, confusion - treat with 15 grams of fast carb, recheck in 15 minutes, and call your prescriber.
If you have insulin or a sulfonylurea on top of metformin, the additive effect matters more. Stack three glucose-lowering agents (metformin + sulfonylurea + ALA) and the lows can be significant. In that case, ask your prescriber whether the sulfonylurea dose should come down first.
Which specific products are affected?
ALA products come in two forms: R-lipoic acid (the biologically active isomer, usually 100-300 mg) and racemic alpha-lipoic acid (a 50/50 mix of R and S, usually 300-600 mg). Both forms have the same potential interaction with metformin. Common brands include Doctor's Best, Jarrow Formulas, NOW Foods, Pure Encapsulations, and Thorne. "Glucose support" combination supplements often pair ALA with chromium, cinnamon, berberine, or biotin - any of these stacks compound the metformin interaction.
On the metformin side, the interaction applies to all forms: immediate-release metformin, extended-release metformin (Glucophage XR, Glumetza, Fortamet), and combination products containing metformin such as Janumet (metformin/sitagliptin), Kombiglyze (metformin/saxagliptin), Synjardy (metformin/empagliflozin), and metformin/glipizide. Combination products with a sulfonylurea are the highest-risk category for an ALA add-on.
The bottom line
Alpha-lipoic acid is one of the better-studied supplements for diabetic neuropathy and the interaction with metformin is real but generally mild. Tell your prescriber, monitor your sugars for the first 4-6 weeks, and pay extra attention if you are thin, elderly, on a beta-blocker, or taking insulin or a sulfonylurea alongside metformin. For most patients the combination is well-tolerated; the risk is not the combination itself but failing to flag it to your care team.